GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Additional Paid-In Capital

ABL Bio (XKRX:298380) Additional Paid-In Capital : ₩366,410 Mil(As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Additional Paid-In Capital?


ABL Bio's quarterly additional paid-in capital stayed the same from Dec. 2023 (₩363,760 Mil) to Mar. 2024 (₩363,760 Mil) but then increased from Mar. 2024 (₩363,760 Mil) to Jun. 2024 (₩366,410 Mil).

ABL Bio's annual additional paid-in capital increased from Dec. 2021 (₩348,732 Mil) to Dec. 2022 (₩361,173 Mil) and increased from Dec. 2022 (₩361,173 Mil) to Dec. 2023 (₩363,760 Mil).


ABL Bio Additional Paid-In Capital Historical Data

The historical data trend for ABL Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Additional Paid-In Capital Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 334,393.31 342,464.95 348,732.11 361,172.88 363,759.65

ABL Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 362,766.36 363,759.65 363,759.65 363,759.65 366,409.65

ABL Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

ABL Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ABL Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Bio Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio Headlines

No Headlines